Company intelligence / Profile preview
Renhaim
Gangseo District, Seoul, South Korearenhaim.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Renhaim is advancing a pipeline of novel therapeutics centered on proprietary mRNA synthesis and delivery technologies. Its lead program is RTX-V002, a personalized blood cancer vaccine expected to enter phase 1 trials in 2025. The company also has a BAFFR-targeted CAR-T cell therapy currently in clinical trials and an early-stage disease-modifying osteoarthritis drug using the mRNA platform. The company’s approach leverages open innovation with academic leaders such as Larry W. Kwak of City of Hope and technology transfer from PeproMene Bio.
- Therapeutic areas
- HematologyRheumatologyOncology
- Modalities
- mRNA-based drugsCAR-T cell therapyVaccineCell therapySmall molecule
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
PeproMene Bio (technology transfer for BAFFR CAR-T)TriLink BioTechnologies (mRNA synthesis technology license)
Beyond the preview
Go deeper on Renhaim.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Renhaim.